Purple Biotech Ltd (TASE: PPBT)
Health Care · Pharmaceuticals · IL
₪0.01
0.00% today · -9.1% 1Y
Purple Biotech Ltd (TASE: PPBT) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $10.54M and employs 10 people.
Over the last twelve months the share price has lost 9.1%, trading between 0.01 and 0.02.
Tweenvest scores Purple Biotech Ltd across four factors: quality 37/100, value 61/100. Its strongest factor is value.
PPBT price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $10.54M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -0.01
- Dividend yield
- —
- Beta (5Y)
- -0.55
- 52-week high
- ₪0.02
- 52-week low
- ₪0.01
- Avg volume (3M)
- —
- Shares outstanding
- 3.24B
- Employees
- 10
- Next earnings
- —
About Purple Biotech Ltd
Purple Biotech Ltd., a clinical-stage company, is focused on creating therapies for cancer patients in the United States, specifically addressing challenges like tumor immune evasion and drug resistance. Its diverse oncology pipeline includes CM24, a humanized monoclonal antibody that targets and blocks carcinoembryonic antigen related cell adhesion molecule 1 (CEACAM1). Currently in Phase 2 clinical trials, CM24 is being investigated as a combination therapy with anti-PD-1 checkpoint inhibitors for treating pancreatic ductal adenocarcinoma. Another candidate is NT219, a small molecule compound in Phase 1/2 clinical trials, which functions by inhibiting insulin receptor substrate 1 and 2 (IRS1/2) and signal transducer and activator of transcription (STAT). This compound is being developed for recurrent and/or metastatic squamous cell carcinoma of the head and neck, or colorectal adenocarcinoma. Furthermore, IM1240, a multi-valent antibody designed to activate an anti-tumoral immune response against 5T4-positive tumors, is in its preclinical stage. The company has established significant collaborations, including an agreement with Bristol Myers Squibb Company for Phase 2 clinical trials to assess CM24 in combination with the PD-1 inhibitor nivolumab and chemotherapy, as well as a partnership with Mor Research Applications. Formerly known as Kitov Pharma Ltd., the company adopted the name Purple Biotech Ltd. in December 2020 and is headquartered in Rehovot, Israel.
- ISIN
- IL0007650166
- Founded
- 1968
- Listed since
- Aug 12, 2002
- Exchange
- The Tel-Aviv Stock Exchange
- Currency
- ILS
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| DIOD Maker of Eco-Friendly Equipment and Nutrition Public Joint Stock CompanyMISX: DIOD | $10.74M | RUB— | — |
| Advicenne S.A.ENXTPA: ALDVI | $10.73M | €0.66 | -3.80% |
| Asston Pharmaceuticals LimitedBSE: 544445 | $10.69M | Rs94.75 | -2.72% |
| Vaishali Pharma LimitedNSEI: VAISHALI | $10.68M | Rs7.92 | -5.49% |
| Sotac Pharmaceuticals LimitedNSEI: SOTAC | $10.33M | Rs90.05 | — |
| Veerhealth Care LimitedBSE: 511523 | $10.24M | Rs49.57 | -0.62% |
| Adial Pharmaceuticals, Inc.NasdaqCM: ADIL | $10.24M | $3.90 | -1.76% |
| Libra Infusions LimitedDSE: LIBRAINFU | $10.08M | Tk551.00 | -2.53% |
Figures last refreshed Oct 11, 2026.